NuScale
SMR
$12.72
-6.26%
NuScale Power Corporation is a developer of proprietary small modular reactor (SMR) technology, operating within the Renewable Utilities industry with a focus on delivering carbon-free nuclear power. The company is a pioneering disruptor in the advanced nuclear energy sector, aiming to commercialize its scalable and passively safe reactor modules. The current investor narrative is intensely focused on the company's path to commercialization, characterized by significant cash burn, project delays, and a stock price that has collapsed from its highs, creating a high-risk, high-reward debate between long-term potential and near-term financial sustainability.…
SMR
NuScale
$12.72
Related headlines
Investment Opinion: Should I buy SMR Today?
Rating: Hold. The core thesis is that NuScale is a purely speculative, binary option on long-term SMR commercialization, not a current business, making it unsuitable for most investors at its current elevated valuation.
The Hold rating is anchored by the extreme disconnect between valuation (73.70x PS) and fundamentals (negative margins, -94.7% revenue growth). Supporting evidence includes the catastrophic quarterly revenue decline to $1.81 million, a gross margin compression into negative territory at -3.37%, and a cash burn rate of -$460 million TTM. While the balance sheet is strong with zero debt and $841 million in cash, and analysts project future revenue over $1.2 billion, these positives are entirely forward-looking and do not justify the current premium.
The two biggest risks that invalidate a Buy thesis are 1) further revenue disappointments or project delays extending the cash runway cliff, and 2) a failure to secure new financing before cash is depleted, leading to catastrophic dilution. This Hold would upgrade to a speculative Buy only if the PS ratio compressed below 20x while the cash runway and project timeline remained intact, or if a major, funded commercial order was secured. It would downgrade to Sell on a breakdown below the $8.85 support level or an acceleration in quarterly cash burn. The stock is grossly overvalued relative to any conventional metric, pricing in near-perfect execution years in advance.
Sign up to view all
SMR 12-Month Price Forecast
The AI assessment is bearish due to the profound disconnect between speculative valuation and deteriorating present reality. While the long-term potential in SMR technology is credible, the path to commercialization is fraught with risk, time, and capital needs that the current stock price does not adequately discount. The high beta and severe downtrend suggest the market is progressively pricing in a higher probability of failure or extreme dilution. Confidence is medium because the company's strong cash position prevents an immediate liquidity crisis, providing a buffer. The stance would upgrade to neutral only upon evidence of stabilizing quarterly financials or a material de-rating in the PS multiple. A shift to bullish would require a concrete, funded order that validates the business model.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on NuScale's 12-month outlook, with a consensus price target around $16.54 and implied upside of +30.0% versus the current price.
Average Target
$16.54
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$10 - $17
Analyst target range
Insufficient analyst coverage data is available to provide a meaningful consensus target price, recommendation breakdown, or implied upside/downside. The provided data includes five analysts with revenue and EPS estimates but lacks the critical target price and rating information typically used for this section. This limited coverage is characteristic of a highly speculative, pre-revenue company like NuScale, leading to higher stock price volatility and less efficient price discovery as the investment thesis is driven by long-dated binary outcomes rather than near-term financial metrics.
Bulls vs Bears: SMR Investment Factors
The investment debate for NuScale is a classic high-risk, high-reward binary bet on an unproven technology. The bear case currently holds stronger evidence, grounded in catastrophic near-term financials, an unsustainable cash burn rate, and an extreme valuation that ignores present reality. However, the bull case rests on a transformative long-term opportunity, a debt-free balance sheet with substantial cash, and analyst projections for billion-dollar revenues. The single most important tension is the race against time: whether NuScale's $841 million cash hoard can fund operations long enough to bridge the gap to commercial deployment before investor patience and capital are exhausted. The resolution of this timeline risk will ultimately determine if the stock is a zero or a multi-bagger.
Bullish
- Zero Debt, Strong Cash Position: The company has a pristine balance sheet with zero debt and a current ratio of 4.30, indicating ample short-term liquidity. This is supported by a cash position of $841.52 million, providing a multi-year runway to fund its cash burn of -$460.12 million TTM without immediate solvency risk.
- Massive Analyst Revenue Growth Forecast: Analysts project a staggering revenue ramp to an average of $1.21 billion, representing a multi-thousand percent increase from the current quarterly revenue of $1.81 million. This reflects extreme optimism for the commercial success of its SMR technology, with the high estimate reaching $1.87 billion.
- First-Mover Advantage in SMR Niche: As a pioneer with proprietary, NRC-approved SMR technology, NuScale holds a disruptive position in the advanced nuclear energy sector. This regulatory approval and focus on passive safety features create a significant technological and timing moat against potential competitors.
- Deeply Oversold Technical Condition: The stock is down 71.41% over six months and trades just 42% above its 52-week low of $8.85, indicating extreme pessimism is priced in. The recent 1-month gain of 5.15% against a 3-month loss of -37.35% could signal a potential stabilization point for a speculative bounce.
Bearish
- Catastrophic Revenue Collapse: Recent quarterly revenue collapsed -94.72% year-over-year to just $1.81 million, down from $34.22 million. This demonstrates a complete lack of near-term commercial traction and an erratic transition from service to product revenue, undermining any near-term fundamental valuation.
- Extreme Valuation Despite Collapse: The stock trades at a Price-to-Sales ratio of 73.70x and an EV/Sales of 73.88x, an astronomical premium even for a growth stock. This valuation is entirely dependent on future success, as current fundamentals show a gross margin of -3.37% and a net margin of -28.11%.
- Severe Cash Burn & No Profitability: The company is hemorrhaging cash, with TTM Free Cash Flow of -$460.12 million and quarterly net income of -$50.83 million. With zero operating income and negative gross profit in the latest quarter, the business model is entirely pre-revenue and dependent on dilutive equity financing to survive.
- High Volatility & Project Delays: A beta of 2.279 makes the stock more than twice as volatile as the market, amplifying downside risk. Recent news highlights critical project delays and shareholder exits, threatening the commercialization timeline which is estimated to be years away, potentially until 2033 for material revenue.
SMR Technical Analysis
The stock is in a severe and sustained downtrend, with a 1-year price change of -13.42% and a more drastic 6-month decline of -71.41%. The current price of $12.65 sits just 42% above its 52-week low of $8.85, positioning it near the bottom of its annual range, which suggests the stock is deeply oversold but may also be a 'falling knife' given the persistent negative momentum. Recent momentum shows a stark divergence, with a 1-month gain of 5.15% against the backdrop of a 3-month plunge of -37.35%; this minor recent bounce could signal a potential stabilization or a dead-cat bounce within a broader bear market, especially as the stock's beta of 2.279 indicates it is more than twice as volatile as the broader market. Key technical support is clearly defined at the 52-week low of $8.85, while resistance is far overhead at the 52-week high of $57.42; a breakdown below $8.85 would signal a new leg down, while a sustained move above recent highs near $20 would be needed to suggest a meaningful reversal is underway, though the extreme volatility implied by the 2.279 beta warrants caution for risk management.
Beta
2.28
2.28x market volatility
Max Drawdown
-82.9%
Largest decline past year
52-Week Range
$9-$57
Price range past year
Annual Return
-17.6%
Cumulative gain past year
| Period | SMR Return | S&P 500 |
|---|---|---|
| 1m | +11.3% | +8.5% |
| 3m | -35.7% | +2.8% |
| 6m | -66.3% | +4.6% |
| 1y | -17.6% | +32.3% |
| ytd | -22.0% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMR Fundamental Analysis
Revenue growth is highly erratic and currently collapsing, with the most recent quarterly revenue at a mere $1.81 million, representing a staggering year-over-year decline of -94.72%; this precipitous drop from $34.22 million in the year-ago quarter indicates the company's transition from service revenue to product sales is fraught with uncertainty and lack of near-term commercial traction. The company is deeply unprofitable, with a net income of -$50.83 million for the quarter and a gross margin of -3.37%, which turned negative from a positive 91.07% in the prior-year period, highlighting severe margin compression and the pre-revenue nature of its business model as it burns cash on R&D and G&A expenses. The balance sheet shows a strong current ratio of 4.30 and zero debt, but it is hemorrhaging cash with free cash flow over the trailing twelve months at -$460.12 million, indicating a complete dependence on external equity financing to fund operations, as evidenced by the $737.88 million in common stock issued in the latest quarter to bolster its cash position to $841.52 million.
Quarterly Revenue
$1808000.0B
2025-12
Revenue YoY Growth
-0.94%
YoY Comparison
Gross Margin
-0.03%
Latest Quarter
Free Cash Flow
$-460117999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMR Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an astronomical 73.70x, reflecting the market's extreme growth expectations for a company with minimal current revenue, while the forward-looking EV/Sales multiple is similarly elevated at 73.88x. Compared to typical utility or industrial peers, this valuation represents a massive premium, predicated entirely on the future commercial success of its SMR technology, which remains years away from generating material sales. Historically, the stock's own PS ratio has fluctuated wildly, from over 1,200x in late 2025 to around 48x in late 2024; the current 73.70x sits below its recent peak but remains near the upper end of its multi-year range, suggesting the market is still pricing in a significant probability of success despite the recent stock price collapse.
PE
-6.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -75x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company's revenue collapsed -94.72% YoY to $1.81 million last quarter, while gross margin turned negative to -3.37% from a positive 91.07%. This indicates the business has no current commercial engine. The primary risk is financial sustainability: with a TTM Free Cash Flow burn of -$460.12 million, the company's $841.52 million cash provides a runway of less than two years at the current burn rate, necessitating future dilutive equity offerings. The complete dependence on a single, unproven technology (SMR) for all future revenue represents an extreme binary operational risk.
Market & Competitive Risks center on valuation compression and execution failure. Trading at a PS ratio of 73.70x, the stock is priced for flawless success. Any delay, cost overrun, or competitive setback from peers like Rolls-Royce (noted in recent news) could trigger a severe de-rating. The stock's beta of 2.279 makes it hypersensitive to broader market downturns and sector rotations away from speculative growth. Furthermore, as a pre-revenue company in a capital-intensive, heavily regulated industry, it faces persistent macro risks like rising interest rates increasing its cost of capital and potential shifts in government energy policy.
Worst-Case Scenario involves a 'death spiral' where project delays extend, cash burn continues unabated, and the company is forced to raise capital at severely depressed share prices, leading to massive dilution. A loss of a key partner or a critical regulatory setback could halt progress entirely. In this scenario, the stock could realistically retest and break below its 52-week low of $8.85, representing a downside of approximately -30% from the current $12.65. Given the stock's historical max drawdown of -82.86%, an extreme bear case could see losses exceeding -50% if commercialization fails entirely, potentially rendering the equity worthless.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company is burning -$460 million in cash annually with only ~$841 million on hand, creating a finite sub-2-year runway. 2) Commercialization/Execution Risk: The entire business model depends on successfully deploying an unproven technology at scale; any technical, regulatory, or partner delay could be fatal. 3) Valuation & Dilution Risk: The extreme PS multiple of 73.7x leaves the stock vulnerable to severe de-rating, and future equity raises will likely be highly dilutive. 4) Market Risk: A beta of 2.279 means the stock will fall more than twice as hard as the market in a downturn, amplifying losses.
The 12-month forecast is highly volatile and bifurcated. The base case (50% probability) sees the stock range-bound between $10 and $18, driven by news flow but lacking a decisive commercial catalyst. The bear case (30% probability) projects a decline to $5-$9 if project delays accelerate or cash burn worsens, potentially breaking key support. The bull case (20% probability) envisions a rally to $25-$35 on the announcement of a firm commercial order, triggering a short squeeze and sentiment shift. The most likely outcome is the base case, where the company continues its pre-revenue development phase without a near-term resolution to its fundamental challenges.
SMR is dramatically overvalued by any conventional measure of current business performance. With a trailing PS ratio of 73.70x and negative profitability across all margins, the market is pricing in flawless execution of a commercial rollout that is still years in the future. Compared to utility or industrial peers, this represents an extreme premium. The valuation implies the market expects the company to rapidly achieve the analyst-projected $1.2+ billion in annual revenue without significant further dilution or delays. Any stumble will cause this premium to compress violently.
SMR is not a good stock to buy for the vast majority of investors seeking capital preservation or growth based on fundamentals. It is a highly speculative instrument with a current Price-to-Sales ratio of 73.7x despite a -94.7% collapse in quarterly revenue. The implied upside, based on analyst long-term revenue projections over $1.2 billion, is massive but also highly uncertain and years away. It could only be considered a 'good buy' for a very specific investor: one with a high-risk tolerance, a decade-long investment horizon, a firm belief in the SMR thesis, and the portfolio capacity to treat the position as a venture-style bet that could go to zero.
SMR is unsuitable for short-term investment due to its extreme volatility (beta 2.279), lack of near-term catalysts, and high risk of capital loss. It pays no dividend and has no earnings visibility. The investment thesis is inherently long-term, based on a commercialization timeline that may extend to 2033. Therefore, it is only suitable for a long-term, speculative holding period of 7-10 years, matching the time needed to validate or invalidate its technology and business model. Even for long-term holders, it should constitute only a very small, risk-capital portion of a diversified portfolio.